Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. (PLX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · PLX · as of Sep 30, 2025
Ownership Breakdown
81
Institutional Holders
▲ 16 vs Q2
$30.91M
Total Inst. Value
▲ $13.29M vs Q2
80.57M
Shares Outstanding
freeFloat 90.27%
13.93M
13F Shares Held
▲ 2.02M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
PLX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. biological products, (no diagnostic substances) | 3.55M | 4.51% | 4.51% | $7.88B | Nov 12, 2025 | ▲ 181.4K |
OPALEYE MANAGEMENT INC. biological products, (no diagnostic substances) | 2.58M | 3.28% | 3.28% | $5.73B | Nov 14, 2025 | NEW |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 1.32M | 1.67% | 1.67% | $2.92B | Nov 13, 2025 | ▼ 299.6K |
NORTHERN TRUST CORP biological products, (no diagnostic substances) | 902.5K | 1.15% | 1.15% | $2.00B | Nov 14, 2025 | ▼ 177.3K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 819.8K | 1.04% | 1.04% | $1.82B | Nov 12, 2025 | ▼ 6.6K |
STRATOS WEALTH PARTNERS, LTD. biological products, (no diagnostic substances) | 500.0K | 63.56% | 63.56% | $1.11B | Nov 6, 2025 | ▲ 150.0K |
STATE STREET CORP biological products, (no diagnostic substances) | 498.5K | 63.38% | 63.38% | $1.11B | Nov 14, 2025 | ▲ 54.3K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 464.4K | 59.04% | 59.04% | $1.03B | Nov 7, 2025 | ▼ 20.4K |
CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. biological products, (no diagnostic substances) | 400.4K | 50.90% | 50.90% | $888.88M | Nov 13, 2025 | ▼ 95.8K |
UBS GROUP AG biological products, (no diagnostic substances) | 190.3K | 24.19% | 24.19% | $422.41M | Nov 13, 2025 | ▲ 115.1K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
14
Increased
+710.6K shares7
New Positions
first time holders20
Decreased
−1.50M shares0
Sold Out
fully exitedNet shares change (top 50)
784.8K
+710.6K / −1.50M
Net new holders
+1
7 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
PLX insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
1
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Bashan Dror PRESIDENT AND CEO | Dec 19, 2025 | Purchase | 56,000 | $1.81 | $101.4K | 188.5K | Form 4 ↗ |
Bar-Shalev Amos director | Nov 18, 2025 | Sale | 168 | $1.87 | $314.16 | 0 | Form 4 ↗ |
Melincoff Gwen A director | Sep 3, 2025 | Award | 15,000 | $1.64 | $24.6K | 15.0K | Form 4 ↗ |
Forster Eliot director | Sep 3, 2025 | Award | 15,000 | $1.64 | $24.6K | 15.0K | Form 4 ↗ |
Forster Eliot director | Sep 3, 2025 | Award | 7,500 | — | — | 7.5K | Form 4 ↗ |
Melincoff Gwen A director | Sep 3, 2025 | Award | 7,500 | — | — | 7.5K | Form 4 ↗ |
Boudes Pol F director | Sep 3, 2025 | Award | 15,000 | $1.64 | $24.6K | 15.0K | Form 4 ↗ |
Boudes Pol F director | Sep 3, 2025 | Award | 7,500 | — | — | 7.5K | Form 4 ↗ |
Elze Christian director | Sep 3, 2025 | Award | 15,000 | $1.64 | $24.6K | 15.0K | Form 4 ↗ |
Schwartz Aharon director | Sep 3, 2025 | Award | 15,000 | $1.64 | $24.6K | 15.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Protalix BioTherapeutics, Inc. (PLX) is primarily owned by institutional investors, who hold approximately 17.3% of total shares outstanding. Company insiders own approximately 9.73%, while retail and public investors account for the remaining 72.99%.
The largest institutional shareholder of Protalix BioTherapeutics, Inc. is BLACKROCK, INC., holding approximately 3.55 million shares — equal to 4.51% of outstanding shares — as of September 30, 2025.
A total of 81 institutional investors currently hold PLX stock, with a combined institutional value of approximately $30,914,125 as of the most recent 13F filing period.
Frequently asked questions
PLX ownershipProtalix BioTherapeutics, Inc. (PLX) is primarily owned by institutional investors, who hold approximately 17.3% of shares. The largest shareholder is BLACKROCK, INC. with a 4.51% stake. Company insiders hold 9.73%. Data sourced from SEC Form 13F as of September 30, 2025.